Adcytherix Raises EUR 105M Series A to Accelerate Breakthrough Antibody-Drug Conjugate Pipeline with Strategic Focus on Novel Payloads Financing led b...
Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rar...
Azurity Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved FerabrightTM (ferumoxytol injection), the first and...
-Kezar Life Sciences, Inc. a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated di...
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced plans to further increase the impact of Thermo Fisher’s p...
NMPA’s response is based on the Phase 3 DRAGON interim analysis results Topline final data expected in Q4 2025 Belite Bio, Inc. (NASDAQ...
SCYNEXIS to receive a $22 million payment as part of the resolution related to the restart of the Phase 3 MARIO study on invasive candidiasis Scynexis...
NUC-3373 Plus Pembrolizumab Continues to Show Favorable Efficacy and Safety Profile in Heavily Pre-treated Patients Latest Data Cut-Off Shows Patient wi...
-Corventum, Inc., a new medicines company advancing novel therapies to make existing cancer treatments safer and more effective, announced the clea...
Quotient Sciences, a leading global drug development, research and manufacturing accelerator, and Biorasi, a global clinical research organization (CRO),...
-Redefining Allergy Treatment with New Class of Trifunctional ECRIs designed to deliver powerful efficacy, rapid relief and complete control of alle...
Global Phase III trial has enrolled and randomised over 170 patients, reaching an important milestone as this is above the amount needed to conduct the...
EMA approval covers study sites in Germany and Poland as part of the Company’s global Phase 2 RENEW trial Trial will evaluate LTI-03, a first-in...
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-0...
© 2025 Biopharma Boardroom. All Rights Reserved.
